Trade-Ideas LLC identified Celldex Therapeutics ( CLDX) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate. In addition to specific proprietary factors, Trade-Ideas identified Celldex Therapeutics as such a stock due to the following factors:

  • CLDX has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $25.8 million.
  • CLDX has traded 968,366 shares today.
  • CLDX traded in a range 206.6% of the normal price range with a price range of $1.75.
  • CLDX traded above its daily resistance level (quality: 17 days, meaning that the stock is crossing a resistance level set by the last 17 calendar days. The resistance price is defined by the Price - $0.01 at the time of the signal).

Stocks matching the 'Barbarian at the Gate' criteria are worthwhile stocks to watch for a variety of factors including historical back testing and volatility. Trade-Ideas targets these opportunities because the stock is exhibiting an unusual behavior while displaying positive price action. In this case, the stock crossed an important inflection point; namely, 'resistance' while at the same time the range of the stock's movement in price is more than twice its normal size. This large range foreshadows a possible continuation as the stock moves higher.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in CLDX with the Ticky from Trade-Ideas. See the FREE profile for CLDX NOW at Trade-Ideas

More details on CLDX:

Celldex Therapeutics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes novel therapeutics for human health care in the United States. Currently there are 8 analysts that rate Celldex Therapeutics a buy, no analysts rate it a sell, and none rate it a hold.

The average volume for Celldex Therapeutics has been 2.2 million shares per day over the past 30 days. Celldex has a market cap of $1.3 billion and is part of the health care sector and drugs industry. The stock has a beta of 2.92 and a short float of 21.2% with 9.62 days to cover. Shares are down 31.4% year-to-date as of the close of trading on Thursday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com Analysis:

TheStreet Quant Ratings rates Celldex Therapeutics as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, feeble growth in its earnings per share, generally disappointing historical performance in the stock itself and weak operating cash flow.

Highlights from the ratings report include:
  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed compared to the Biotechnology industry average, but is greater than that of the S&P 500. The net income has decreased by 14.4% when compared to the same quarter one year ago, dropping from -$28.27 million to -$32.36 million.
  • CELLDEX THERAPEUTICS INC' earnings per share from the most recent quarter came in slightly below the year earlier quarter. Earnings per share have declined over the last two years. We anticipate that this should continue in the coming year. During the past fiscal year, CELLDEX THERAPEUTICS INC reported poor results of -$1.32 versus -$1.03 in the prior year. For the next year, the market is expecting a contraction of 3.8% in earnings (-$1.37 versus -$1.32).
  • Looking at the price performance of CLDX's shares over the past 12 months, there is not much good news to report: the stock is down 27.13%, and it has underformed the S&P 500 Index. In addition, the company's earnings per share are lower today than the year-earlier quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.
  • Net operating cash flow has decreased to -$24.76 million or 18.72% when compared to the same quarter last year. Despite a decrease in cash flow of 18.72%, CELLDEX THERAPEUTICS INC is still significantly exceeding the industry average of -79.03%.
  • The return on equity has improved slightly when compared to the same quarter one year prior. This can be construed as a modest strength in the organization. Compared to other companies in the Biotechnology industry and the overall market, CELLDEX THERAPEUTICS INC's return on equity significantly trails that of both the industry average and the S&P 500.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.